Rosen Law Firm Probes MoonLake Immunotherapeutics After 89.9% Stock Plunge
Rosen Law Firm, renowned for its securities class actions, is now investigating potential claims against MoonLake Immunotherapeutics (NASDAQ: MLTX). The probe follows a dramatic 89.9% stock plunge on September 29, 2025, after the company revealed disappointing clinical trial results.
MoonLake's stock nosedived after it announced that a key clinical trial did not meet statistical significance. This revelation has raised questions about the company's business information, prompting Rosen Law Firm's investigation.
The law firm has a proven track record in securities class actions, having recovered hundreds of millions of dollars for investors. They are exploring whether investors who purchased MoonLake securities may be entitled to compensation through a contingency fee arrangement.
Meanwhile, Robbins Geller Rudman & Dowd LLP has filed a lawsuit against MoonLake Immunotherapeutics, alleging that the company falsified business information, leading to losses for shareholders.
Rosen Law Firm's investigation into MoonLake Immunotherapeutics is ongoing. Investors who purchased the company's securities may be eligible for compensation. The lawsuit filed by Robbins Geller Rudman & Dowd LLP adds another layer to the ongoing saga surrounding MoonLake's business practices.
